Dr. John Joseph Sramek is a pharmacist who is specialized in Pharmacotherapy in Oxnard, California. Patients can reach him at 5031 Shoreline Way, Oxnard or contact him on 805-984-3279. Active license number of Dr. John Joseph Sramek is RPH31194 for Pharmacotherapy in California. Dr. John Joseph Sramek is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Dr. John Joseph Sramek speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. John Joseph Sramek are as mentioned below.
NPI Number:
1952625923
NPI Enumeration Date:
19 Mar, 2010
NPI Last Update On:
19 Mar, 2010
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. John Joseph Sramek are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
RPH31194
California
Primary
Psychiatric
RPH31194
California
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
5031 Shoreline Way, Oxnard, California
Zip:
93035-2842
Phone Number:
805-815-4341
Fax Number:
--
Patients can reach Dr. John Joseph Sramek at 5031 Shoreline Way, Oxnard, California or can call on phone at 805-984-3279.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.